Delcath Systems, Inc. DCTH
21.49 USD -0.29 (-1.31%)
Nov 12, 2026, 2:14 PM EST
21.44 Day range 22.51
8.12 52-week range 22.51
- YTD
- +112.72%
- 1 year
- +150.12%
News
zacks.com Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy? Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 27.7%: Read This Before Placing a Bet The consensus price target hints at a 27.7% upside potential for Delcath Systems (DCTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
businesswire.com Delcath Systems to Be Featured on “Health Uncensored with Dr. Drew” in Segment Highlighting Advances in Liver-Directed Cancer Treatment QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the…
benzinga.com HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $36 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the price target from $32 to $36.
benzinga.com Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results U.S. stocks surged Monday, led by a 2.1% S&P 500 gain; NRG jumped on strong results, while Zura Bio plunged 75% after trial failures.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com CNH Industrial, Planet Labs, Ferguson Enterprises And Other Big Stocks Moving Higher On Monday U.S. stocks rallied Monday; CNH surged 13.5% after strong Q3 results and raised guidance, while several stocks posted double-digit gains.
seekingalpha.com Delcath Systems, Inc. (DCTH) Q3 2026 Earnings Call Transcript Delcath Systems, Inc. (DCTH) Q3 2026 Earnings Call Transcript
benzinga.com BTIG Maintains Buy on Delcath Systems, Raises Price Target to $25 BTIG analyst Marie Thibault maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the price target from $21 to $25.
marketbeat.com Delcath Systems Q3 Earnings Call Highlights Delcath Systems NASDAQ: DCTH reported record third-quarter revenue of $35.1 million, up 71% from a year earlier, as use of its HEPZATO KIT increased across U.S. treatment centers. The company also…
zacks.com Delcath Systems, Inc. (DCTH) Q3 Earnings and Revenues Top Estimates Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to earnings of $0.02 per share a year…
benzinga.com Delcath Systems Q3 2026 Earnings Call Transcript Delcath Systems (NASDAQ:DCTH) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Delcath Systems Raises FY2026 Sales Guidance from $104.000M-$108.000M to $115.000M-$117.000M vs $106.507M Est Delcath Systems (NASDAQ:DCTH) raises FY2026 sales outlook from $104.000 million-$108.000 million to $115.000 million-$117.000 million vs $106.507 million estimate.
benzinga.com Delcath Systems Q3 EPS $0.17 Beats $(0.09) Estimate, Sales $35.102M Beat $26.027M Estimate Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $(0.09) by 312.5 percent. This is a 750 percent increase over earnings of…
businesswire.com Delcath Systems Reports Third Quarter 2026 Results and Business Highlights QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial…
benzinga.com Delcath Systems Presents Data Regarding Its Clinical Development Programs At European Society For Medical Oncology Congress 2026; Presents Publication Of Analysis Of Percutaneous Hepatic Perfusion With Melphalan Using CHEMOSAT Hepatic Delivery Systems Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical…
benzinga.com Delcath Systems Q2 2026 Earnings Call Transcript Delcath Systems (NASDAQ:DCTH) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide…
benzinga.com HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $32 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the price target from $30 to $32.
benzinga.com BTIG Maintains Buy on Delcath Systems, Raises Price Target to $21 BTIG analyst Marie Thibault maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the price target from $17 to $21.- benzinga.com Delcath Systems Q2 EPS $0.07 Beats $(0.09) Estimate, Sales $29.133M Beat $26.259M Estimate Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.09) by 177.78 percent. This is unchanged from the same period last year.…
- benzinga.com Delcath Systems Sees FY2026 Sales $104.000M-$108.000M vs $103.242M Est Delcath Systems (NASDAQ:DCTH) sees FY2026 sales of $104.000 million-$108.000 million vs $103.242 million analyst estimate.
- benzinga.com Delcath Systems Q1 EPS $(0.03) Beats $(0.10) Estimate, Sales $24.994M Beat $23.383M Estimate Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.10) by 70 percent. This is a 200 percent decrease over earnings of $0.03…
benzinga.com Delcath Systems' CHEMOSAT M-PHP Recognized As Recommended Liver-Directed Therapy For Metastatic Uveal Melanoma In 2026 ESMO–EURACAN Guidelines Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT® Hepatic Delivery System for…- benzinga.com BTIG Maintains Buy on Delcath Systems, Lowers Price Target to $19 BTIG analyst Marie Thibault maintains Delcath Systems (NASDAQ:DCTH) with a Buy and lowers the price target from $23 to $19.
- benzinga.com Delcath Systems FY2026 Total CHEMOSAT and HEPZATO KIT Revenue expected to be more than $100.000M vs $112.895M Est Delcath Systems (NASDAQ:DCTH) FY2026 Total CHEMOSAT and HEPZATO KIT Revenue expected to be more than $100.000M vs $112.895M Est
- benzinga.com Delcath Systems Q4 EPS $(0.05) Beats $(0.06) Estimate, Sales $20.728M Beat $20.326M Estimate Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 19.35 percent. This is a 54.55 percent increase over losses of…
benzinga.com Delcath Systems Q4 Earnings Assessment 
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com HC Wainwright & Co. Reiterates Buy on Delcath Systems, Maintains $30 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $30 price target.
benzinga.com Under the Radar: 3 Microcap Growers Passing a Tough Test - benzinga.com Delcath Systems Publishes Phase 3 FOCUS Subgroup Analyses Showing Consistent Efficacy And Safety Of HEPZATO KIT In Unresectable Metastatic Uveal Melanoma In The Journal Of Cancer Research And Clinical Oncology Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication…
- benzinga.com Delcath Systems 10-Year Data From Retrospective Study On Patients With Liver-Dominant Metastatic Uveal Melanoma Shows Safety, Efficacy Of CHEMOSAT Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session - benzinga.com Delcath Systems Announces $25M Buyback Plan Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath") an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of…
- benzinga.com Delcath Systems Announces Retrospective Study From The University Of Tubingen, Analyzing Long-Term Survivors With Liver Metastases From Uveal Melanoma Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication…
- benzinga.com Stephens & Co. Maintains Overweight on Delcath Systems, Lowers Price Target to $18 Stephens & Co. analyst Sudan Loganathan maintains Delcath Systems (NASDAQ:DCTH) with a Overweight and lowers the price target from $25 to $18.
- benzinga.com Delcath Systems Q3 EPS $0.02 Beats $0.01 Estimate, Sales $20.563M Miss $20.907M Estimate Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.01 by 185.71 percent. This is a 66.67 percent decrease over earnings of…
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com Canaccord Genuity Maintains Buy on Delcath Systems, Maintains $21 Price Target Canaccord Genuity analyst John Newman maintains Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $21 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Delcath Systems, Lowers Price Target to $30 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and lowers the price target from $31 to $30.
benzinga.com Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket - benzinga.com Reported Saturday, Delcath Systems Posts $20.5M Q3 Revenue, $0.8M Net Income And 87% Gross Margin; Sees 2025 Revenue Outlook Of $83M–$85M With 150% Treatment Volume Growth Forecast Preliminary Third Quarter Financial Results (unaudited)Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 millionHEPZATO KIT revenue of $19.2 millionCHEMOSAT revenue of $1.3 millionGross…
- benzinga.com Delcath Systems Announces The Acceptance Of An Oral Presentation On Results From The Investigator-Initiated CHOPIN Randomized Phase 2 Trial At The 2025 European Society For Medical Oncology Annual Congress Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the acceptance of an oral presentation on…
- benzinga.com HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $31 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the price target from $29 to $31.
- benzinga.com Earnings Scheduled For August 6, 2025
benzinga.com Tesla To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Friday - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Earnings Scheduled For May 8, 2025
benzinga.com Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com Earnings Scheduled For March 6, 2025